Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.54 |
| ▸ | NOS3 | P29474 | 6/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6619735 | 0.74 | NOS1 (0.76) | NOS1NOS3CHRM2CHRM4HTR2A | |
| SCHEMBL6618047 | 0.74 | NOS1 (0.74) | NOS1NOS3CHRM2CHRM4HTR2A | |
| SCHEMBL10979646 | 0.73 | CA1 (0.39) | CHRM2HTR2AKCNH2HTR2CMITF | |
| SCHEMBL10974784 | 0.73 | CA1 (0.39) | CHRM2HTR2AKCNH2HTR2CTDP1 | |
| SCHEMBL6618161 | 0.72 | NOS1 (1.00) | NOS1NOS3CHRM2CHRM4HTR2A | |
| SCHEMBL6621573 | 0.69 | NOS1 (0.77) | NOS1NOS3CHRM2CHRM4HTR2A | |
| SCHEMBL6620545 | 0.69 | NOS1 (1.00) | NOS1NOS3CHRM2CHRM4HTR2A | |
| SCHEMBL6621185 | 0.69 | NOS1 (0.60) | NOS1NOS3CHRM2CHRM4HTR2A | |
| SCHEMBL6621188 | 0.69 | NOS1 (0.60) | NOS1NOS3CHRM2CHRM4HTR2A | |
| SCHEMBL6621240 | 0.69 | NOS1 (0.57) | NOS1NOS3CHRM2CHRM4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891332-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6465491-B2 | NITRIC OXIDE SYNTHASE INHIBITOR; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | LOWE JOHN A (US) | 2001-10-25 | — | — | US | disclosed |
| US-6235747-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | NOS2, NOS3, NOS1 | NOS1 3/4885NOS3 2/4885CHRM2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.